Europe Diagnostic Labs Market is estimated to be USD 45.0 billion by 2034 and is anticipated to register a CAGR of 2.9% during the forecast period.

The Europe IVD market report segments the industry into By Test Type (Clinical Chemistry, Molecular Diagnostics, Hematology, and more), By Product (Instrument, Reagents, and more), By Usability (Disposable IVD Devices, and more), By Application (Infectious Disease, Diabetes, and more), By End User (Diagnostic Laboratories, and more) and Geography.

The global diagnostic labs market is a rapidly expanding sector, driven by several key factors. Rising prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer necessitates frequent diagnostic testing, fueling market growth. Technological advancements, including the development of sophisticated and automated testing equipment, point-of-care diagnostics, and advanced molecular diagnostics, are significantly improving accuracy, speed, and efficiency, leading to increased adoption. Furthermore, the increasing geriatric population globally requires more extensive diagnostic services, adding to market demand. The COVID-19 pandemic, while initially disruptive, also accelerated the adoption of telehealth and remote patient monitoring, leading to increased demand for certain diagnostic services and driving innovation in the sector. Growth is segmented across various application areas, including general and clinical testing (which holds the largest share due to routine checkups and disease management), specialized testing (covering niche areas like genetic testing and oncology diagnostics), non-invasive prenatal testing (driven by increasing awareness and technological progress), and COVID-19 testing (although this segment's growth is expected to slow as the pandemic becomes endemic). The market is also diversified across laboratory types, with single/independent labs, hospital-based labs, and physician office labs all playing significant roles. Competition within the market is intense, with both large multinational corporations and regional players vying for market share. Regulatory hurdles and data privacy concerns, however, act as restraints. Regional market analysis reveals significant variations in growth rates. North America, particularly the United States, is currently the largest market, driven by high healthcare expenditure and advanced healthcare infrastructure. However, emerging economies in Asia-Pacific, notably China and India, are demonstrating rapid growth due to rising disposable incomes, increasing healthcare awareness, and burgeoning healthcare infrastructure development. Europe also holds a substantial market share, but growth is relatively more moderate compared to the Asia-Pacific region. Overall, the diagnostic labs market exhibits a positive outlook, with substantial growth potential projected over the coming years. Factors like expanding healthcare infrastructure in developing nations and continuous technological innovation are expected to propel market expansion and create new opportunities for market players.

The Europe Molecular Diagnostics Market report segments the industry into By Technology (In Situ Hybridization, Chips and Microarrays, and more), By Application (Infectious Diseases, Oncology, and more), By Product (Instruments, Reagents, and more), By End User (Hospitals, Laboratories, and more), and By Geography (Germany, United Kingdom, and more).

The europe laboratory developed tests market expansion is anticipated to achieve USD 7.59 billion by 2032 with a CAGR of 7.7% by 2032.

Learn more about Market Research Intellect's Diagnostic Labs Market Report, valued at USD 55 billion in 2024, and set to grow to USD 90 billion by 2033 with a CAGR of 6.5% (2026-2033).

Laboratory Diagnostics Market Outlook

The global laboratory diagnostics market size was valued at approximately USD 55 billion in 2023 and is anticipated to reach around USD 90 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.6%. The market's growth is being driven by the increasing prevalence of chronic diseases, advancements in diagnostic technologies, and the rising demand for early and accurate disease detection.

One of the primary growth factors driving the laboratory diagnostics market is the rising incidence of chronic and infectious diseases worldwide. Chronic diseases such as diabetes, cardiovascular diseases, and cancer require regular monitoring and early diagnosis, which in turn fuels the demand for advanced diagnostic tests. Additionally, the COVID-19 pandemic has further emphasized the importance of robust diagnostic systems, leading to increased investment in this sector. The need for timely diagnosis and treatment of diseases has placed laboratory diagnostics at the forefront of the healthcare industry.

Technological advancements in diagnostic instruments and techniques are significantly contributing to market growth. Innovations such as point-of-care testing, high-throughput screening, and automated laboratory systems have enhanced the efficiency and accuracy of diagnostic procedures. Moreover, the integration of artificial intelligence and machine learning in diagnostics is further revolutionizing the market, enabling faster and more precise results. These technological advancements are not only improving patient outcomes but also reducing the overall cost of healthcare services.

The aging global population is another crucial factor propelling the laboratory diagnostics market. As the elderly population is more susceptible to various diseases, there is a heightened need for routine diagnostic tests to manage and monitor their health conditions. The growing awareness about preventive healthcare among the aging population is also driving the demand for diagnostic services. Governments and healthcare organizations are increasingly focusing on preventive measures, further boosting the market's growth potential.

Regionally, North America holds a significant share in the laboratory diagnostics market, driven by the presence of advanced healthcare infrastructure and high healthcare expenditure. The Asia Pacific region is expected to witness the fastest growth during the forecast period due to the increasing healthcare investments, rising awareness about early disease diagnosis, and improving healthcare facilities. Europe also represents a substantial market share due to a well-established healthcare system and high adoption rate of advanced diagnostic technologies.

Product Type Analysis

The laboratory diagnostics market can be segmented by product type into clinical chemistry, immunoassays, hematology, coagulation, microbiology, molecular diagnostics, and others. Clinical chemistry is one of the largest segments, owing to its widespread use in routine health check-ups and chronic disease monitoring. Tests under this segment include blood glucose tests, cholesterol tests, and liver function tests, among others. The increasing prevalence of lifestyle diseases such as diabetes and cardiovascular disorders is driving the demand for clinical chemistry tests. Innovations in this segment, such as automated analyzers, have further streamlined diagnostic processes, making them quicker and more reliable.

Immunoassays are another crucial segment within laboratory diagnostics. These tests are pivotal in detecting and measuring specific proteins or molecules, offering highly accurate results. They are extensively used in diagnosing infectious diseases, autoimmune disorders, and hormone-related conditions. The advancements in assay technologies, including the development of multiplex assays and high-sensitivity immunoassays, are enhancing the diagnostic capabilities and expanding the application scope of immunoassays. This segment is expected to witness robust growth due to the rising demand for early and precise disease detection.

Hematology and coagulation tests play an essential role in diagnosing blood-related disorders and monitoring treatment efficacy. Hematology tests, including complete blood count (CBC), are commonly used to diagnose conditions such as anemia, infections, and leukemia. Coagulation tests help in assessing blood clotting functions, crucial for patients with bleeding disorders or those undergoing surgery. The increasing prevalence of blood-related disorders and the growing

The report covers Europe Crop Protection Market Size, Europe Phytosanitary Market Size, Europe Agrochemical Revenue.

The Clinical Diagnostics Market report segments the industry into By Test (Lipid Panel, Liver Panel, Renal Panel, Complete Blood Count, Electrolyte Testing, Infectious Disease Testing, Other Tests), By Product (Instruments, Reagents, Other Products), By End User (Hospital Laboratory, Diagnostic Laboratory, Point-of-care Testing, Other End Users), and Geography (North America, Europe, Asia-Pacific, and more).

The global diagnostic labs market is projected to reach a value of XXX million by 2033, exhibiting a CAGR of XX% during the forecast period (2025-2033). Key drivers of this growth include rising prevalence of chronic diseases, increasing healthcare spending, technological advancements, and growing awareness of personalized medicine. The increasing demand for accurate and timely diagnosis of diseases is also contributing to the market expansion. The market is segmented based on application (clinical diagnostics, drug discovery, genomics, and others) and type (molecular diagnostics, immunoassays, microscopy, and others). The clinical diagnostics segment holds a significant share due to the widespread use of diagnostic tests in hospitals, clinics, and laboratories. Molecular diagnostics and immunoassays dominate the type segment owing to their high accuracy and specificity. North America is the largest regional market, followed by Europe and Asia Pacific. The presence of well-established healthcare systems and a large population base drive growth in these regions.

Snapshot img

Influenza Diagnostics Market Size 2024-2028

The influenza diagnostics market size is forecast to increase by USD 517.5 million at a CAGR of 7.22% between 2023 and 2028.

The market is experiencing significant growth, driven by the rising incidence of influenza and increasing approvals for innovative diagnostic products. According to various health organizations, influenza affects millions annually, leading to increased demand for accurate and timely diagnostic solutions. This trend is further accentuated by the ongoing COVID-19 pandemic, which has highlighted the importance of rapid and reliable diagnostic tests in controlling the spread of infectious diseases. However, market expansion is not without challenges. A significant barrier lies in the lack of adequate laboratory infrastructure, particularly in developing regions. This issue hampers the widespread adoption of advanced diagnostic technologies and creates opportunities for companies to address this unmet need by investing in affordable, portable, and easy-to-use diagnostic solutions. Furthermore, ongoing research and development efforts in areas such as molecular diagnostics and point-of-care testing are expected to fuel market growth, providing ample opportunities for companies to capitalize on these advancements and cater to the evolving diagnostic needs of healthcare providers and patients.

What will be the Size of the Influenza Diagnostics Market during the forecast period?

Request Free SampleThe market encompasses a range of diagnostic technologies utilized by hospitals and clinics, healthcare providers, diagnostic laboratories, research industries, and healthcare professionals to identify and confirm influenza infections. With the potential for severe illness and respiratory deaths associated with influenza, the demand for accurate and efficient diagnostic tools remains high. The market is driven by advancements in molecular diagnostics, such as polymerase chain reaction (PCR) and nucleic acid sequence-based amplification (NASBA), and rapid diagnostic tests, including rapid antigen tests and serology tests. Sensitivity and specificity are critical factors in the selection of diagnostic tests, with a focus on minimizing false-negative and false-positive results. Regulatory frameworks, such as those established by the World Health Organization, play a crucial role in ensuring the safety and efficacy of diagnostic tests. Product segmentation includes viral culture tests, molecular diagnostics, and rapid diagnostic tests. The market is expected to continue growing due to the ongoing need for effective influenza diagnosis and treatment.

How is this Influenza Diagnostics Industry segmented?

The influenza diagnostics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. End-userHospitals and diagnostic laboratoriesAcademic and research centersHomecareTypePoint-of-care testingImmunodiagnosticsMolecular diagnosticsGeographyNorth AmericaUSCanadaEuropeFranceGermanyAsiaChinaRest of World (ROW)

By End-user Insights

The hospitals and diagnostic laboratories segment is estimated to witness significant growth during the forecast period.The World Health Organization (WHO) highlights the importance of accurate and timely influenza diagnostics in the medical sector. Influenza diagnostics refer to the tests and procedures used to identify influenza viruses, with hospitals and diagnostic laboratories being a significant segment. These institutions handle a substantial number of influenza cases, necessitating efficient and precise diagnostic tools to determine the infection and appropriate treatment interventions. Hospitals and diagnostic laboratories prioritize prompt diagnosis and effective management of influenza cases to mitigate the disease burden, which includes severe illness and respiratory deaths. Influenza diagnostic tests come in various types, including antigen tests, multiplex assays, molecular diagnostic tests, viral culture tests, serology tests, and rapid diagnostic tests. Each test type offers unique advantages in terms of sensitivity and specificity, medical procedures, and time to result. For instance, rapid antigen tests are ideal for point-of-care settings due to their quick turnaround time, while molecular diagnostic assays provide higher sensitivity and specificity. Healthcare providers, including hospitals, clinics, primary care offices, urgent care centers, and diagnostic laboratories, rely on these diagnostic tools to ensure accurate and timely influenza diagnoses. False-negative and false-positive results can impact patient care and public health measures, making it crucial to choose the right diagnostic tool for each application. In The market, various diagnostic instruments and techniques

The Europe In Vitro Diagnostics Market size was valued at USD 26.77 billion in 2023 and is projected to reach USD 28.11 billion by 2032, exhibiting a CAGR of 0.7 % during the forecasts period. In Vitro Diagnostics (IVD) are medical tests conducted on samples taken from the human body, such as blood or tissue, to detect diseases, conditions, and infections. The term in vitro" indicating that these tests are typically performed outside the living organism in a controlled environment, like test tubes or petri dishes. IVDs are essential tools in healthcare, providing critical information for diagnosis, monitoring, and guiding treatment decisions. IVDs range from simple tests, such as pregnancy tests that can be done at home, to more complex analyses carried out in clinical laboratories. They play a pivotal role in the early detection of diseases, management of chronic conditions, and supporting personalized medicine by identifying patients who may benefit from specific treatments.

The Europe Laboratory Developed Tests Market size was valued at USD 4.1 billion in 2023 and is projected to reach USD 6.98 billion by 2032, exhibiting a CAGR of 7.9 % during the forecasts period. The developed and used within a single laboratory tests (LDT) market refers to diagnostic tests that have the European laboratory Europe laboratory market engage the tests that are not available on the market for medical purposes. These tests are vital for the diagnosis and treatment of diseases, particularly in the evolving field of personalized medicine, Orphan diseases, and other specialty diseases. Users are included in areas such as cancer diagnosis, genetic disorders, acute infections, and long-term illnesses. Major factors contributing to the market include innovations in both micro and molecular diagnostics, shifting focus towards precision healthcare, and contractual manufacturing services. It is important to note that standards will continue to be introduced to govern the quality and safety of tests that are being conducted, thus affecting markets. Moreover, the advancement in technologies like NGS and digital PCR is growing the potential and interaction of LDTs in clinical processes. Recent developments include: Innovative Health Initiative (IHI) and UK Research and Innovation (UKRI) funded AD-RIDDLE program provides new solutions in diagnosis and treatment of Alzheimer’s disease , Qiagen NV, a Netherlands-based diagnostic test kits producing company, announced in January 2024, that the U.S. FDA gave clearance about NeuMoDx CT/NG Assay 2.0 for detecting sexually transmitted infections (STI) in the U.S. .

According to Future Market Insights research, during the projected period, the Global point-of-care diagnostics market is expected to grow at a CAGR of 6.8%. The market value is projected to increase from US$ 38.7 Billion in 2023 to US$ 74.8 Billion by 2033. The point-of-care diagnostics market was valued at US$ 36.6 Billion at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 5.8% in 2023.

Data Points	Market Insights
Market Value 2022	US$ 36.6 Billion
Market Value 2023	US$ 38.7 Billion
Market Value 2033	US$ 74.8 Billion
CAGR 2023 to 2033	6.8%
Share of Top 5 Countries	56.5%
Key Players	The key players in the Global Point-of-Care Diagnostics Market Are F. Hoffmann-La Roche Ltd, Becton Dickinson & Company, Cepheid (Danaher),Siemens Healthineers, Abbott, Diasorin S.p.a., Thermo Fisher Scientific Inc. , Qiagen, BIOMÉRIEUX, Hologic Inc., Bio Rad Laboratories, Quidel Corporation, EKF Diagnostics, SEKISUI Diagnostics, DiaSys-Diagnostic Systems GmbH, InBios International, Inc., Jiangsu Mole Bioscience Co., Ltd., ACON Laboratories, Inc., Visby Medical, Inc., UNIMA, INC.

Scope of the Global Point-of-Care Diagnostics Industry Report

Attribute	Details
Forecast Period	2023 to 2033
Historical Data Available for	2012 to 2022
Market Analysis	USD Million for Value
Key Regions Covered	North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East and Africa (MEA)
Key Countries Covered	USA, Canada, Brazil, Mexico, Argentina, Germany, UK, France, Italy, Spain, Russia, BENELUX, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, Türkiye, South Africa, and GCC Countries
Key Segments Covered	Test Type, Sample, Product, End User, Region
Key Companies Profiled	F. Hoffmann-La Roche Ltd Becton Dickinson & Company Cepheid (Danaher) Siemens Healthineers Abbott Diasorin S.p.a. Thermo Fisher Scientific Inc. Qiagen BIOMÉRIEUX Hologic Inc. Bio Rad Laboratories Quidel Corporation EKF Diagnostics SEKISUI Diagnostics DiaSys-Diagnostic Systems GmbH InBios International, Inc. Jiangsu Mole Bioscience Co., Ltd. ACON Laboratories, Inc. Visby Medical, Inc. UNIMA, INC.
Report Coverage	Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Customization & Pricing	Available upon Request

The European molecular diagnostics market, valued at €3.45 billion in 2025, is projected to experience robust growth, exhibiting a compound annual growth rate (CAGR) of 8.96% from 2025 to 2033. This expansion is driven by several key factors. The increasing prevalence of chronic diseases like cancer and infectious diseases, coupled with a rising geriatric population across Europe, fuels the demand for accurate and rapid diagnostic tools. Advancements in molecular diagnostic technologies, such as next-generation sequencing (NGS) and PCR, are improving diagnostic capabilities, leading to earlier disease detection and personalized treatment strategies. Furthermore, increasing government funding for research and development in the field, along with supportive regulatory frameworks, are fostering market growth. The market is segmented by technology (In Situ Hybridization, Chips and Microarrays, Mass Spectrometry, Sequencing, PCR, and Other Technologies), application (Infectious Diseases, Oncology, Pharmacogenomics, Microbiology, Genetic Disease Testing, and Other Applications), product (Instruments, Reagents, and Other Products), and end-user (Hospitals, Laboratories, and Other End-Users). The presence of major players like Abbott Laboratories, Illumina, and Roche, along with a robust research ecosystem, further contributes to the market's dynamism. The market's growth is not without challenges. High costs associated with advanced technologies and the need for skilled professionals can limit market penetration, particularly in resource-constrained settings. Furthermore, stringent regulatory approvals and reimbursement policies can influence market dynamics. However, the increasing adoption of point-of-care diagnostics and the development of cost-effective technologies are expected to mitigate these restraints. Germany, the United Kingdom, and France are expected to dominate the European market due to advanced healthcare infrastructure and substantial investments in molecular diagnostics. The market's future growth will likely depend on continuous technological innovations, expanded access to testing, and efficient regulatory frameworks across various European nations. Recent developments include: In September 2022, SkylineDxv launched Merlin Assay as CE-IVD distributable test kit in Europe. Merlin Assay identifies melanoma (skin cancer) patients with a low risk for nodal metastasis and can safely forgo a sentinel lymph node biopsy (SLNB) surgery., In March 2022, Illumina launched an in-vitro diagnostic test designed to profile cancer mutations and direct patients to targeted therapies in Europe.. Key drivers for this market are: Increasing Demand for Point-of-care Diagnostics, Advancements in Pharmacogenomics and Other Technologies; Possibility of Outbreaks of Bacterial and Viral Epidemics. Potential restraints include: Increasing Demand for Point-of-care Diagnostics, Advancements in Pharmacogenomics and Other Technologies; Possibility of Outbreaks of Bacterial and Viral Epidemics. Notable trends are: The Infectious Disease Segment is Expected to Witness High Growth Over the Forecast Period.

The global medical laboratory testing market is a substantial and rapidly expanding sector, driven by factors such as the rising prevalence of chronic diseases (diabetes, cardiovascular diseases, and cancer), an aging global population necessitating increased diagnostic testing, and advancements in laboratory technologies leading to faster, more accurate, and cost-effective tests. The market is segmented by application (hospital-based, independent, and clinic-based labs) and test type (complete blood count, metabolic panels, etc.), with hospital-based labs currently holding the largest market share due to their comprehensive service offerings and established infrastructure. However, the independent and clinic-based laboratory segments are experiencing significant growth, fueled by increasing demand for convenient and accessible testing options. Technological advancements, such as automation, point-of-care diagnostics, and advanced molecular testing techniques, are further contributing to market expansion. Geographic variations exist, with North America and Europe currently dominating the market due to higher healthcare expenditure and advanced healthcare infrastructure. However, emerging economies in Asia-Pacific and the Middle East & Africa are demonstrating rapid growth potential, driven by rising healthcare awareness, improving healthcare infrastructure, and increasing government initiatives to bolster healthcare access. Market restraints include stringent regulatory requirements for laboratory testing, high operational costs associated with advanced technologies, and the potential for reimbursement challenges. Despite these challenges, the overall market outlook remains positive, with a projected Compound Annual Growth Rate (CAGR) that suggests substantial expansion throughout the forecast period. Key players in the market, including Quest Diagnostics, Laboratory Corporation of America, and Abbott, are actively investing in research and development, strategic acquisitions, and geographical expansion to maintain their competitive edge. This competitive landscape fosters innovation and ensures the delivery of high-quality, accessible laboratory services. The continued development of personalized medicine and early disease detection strategies will further propel market growth in the coming years.

Europe's Veterinary Laboratory Testing Service market USD 2805.36 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031. Rising animal health consciousness, improvements in veterinary diagnostics, and stricter regulations are expected to aid the sales to USD 5376.2million by 2031

The global diagnostic laboratory testing market is experiencing robust growth, driven by factors such as the rising prevalence of chronic diseases, an aging population, technological advancements in diagnostic techniques, and increasing healthcare expenditure. The market size in 2025 is estimated at $250 billion, exhibiting a Compound Annual Growth Rate (CAGR) of 5.5% from 2025 to 2033. This growth is fueled by the increasing demand for accurate and timely diagnostic information, enabling early disease detection and personalized treatment strategies. The market is segmented by test type (urine, blood, tumor markers, others) and application (hospital-based, clinic-based, independent laboratories). Blood tests currently dominate the market, accounting for the largest share due to their widespread application across various disease areas. Technological innovations, such as the development of point-of-care diagnostics and advanced molecular testing, are driving market expansion, particularly within hospital and clinic-based settings. Significant regional variations exist within the market. North America currently holds the largest market share, owing to well-established healthcare infrastructure, high technological adoption rates, and a significant aging population. However, rapidly developing economies in Asia-Pacific are expected to witness substantial growth over the forecast period, driven by expanding healthcare access and rising disposable incomes. The market faces certain restraints, including stringent regulatory approvals for new diagnostic tests, high costs associated with advanced technologies, and the potential for variations in healthcare reimbursement policies across different regions. Nevertheless, the overall outlook for the diagnostic laboratory testing market remains positive, with substantial opportunities for growth and innovation in the coming years. Key players like Siemens Healthineers, Roche, and Abbott Laboratories are strategically investing in research and development to maintain their market leadership.

The global clinical laboratory diagnostics services market is a substantial and rapidly expanding sector, projected to reach a valuation of approximately $250 billion by 2025, exhibiting a compound annual growth rate (CAGR) of 5%. This growth is fueled by several key factors. The increasing prevalence of chronic diseases like diabetes, cardiovascular conditions, and cancer necessitates frequent diagnostic testing, driving demand for laboratory services. Technological advancements, such as the development of sophisticated molecular diagnostics, point-of-care testing, and automation, are enhancing diagnostic accuracy, efficiency, and speed, contributing significantly to market expansion. Furthermore, the rising geriatric population, globally, requires more frequent and extensive diagnostic testing, further stimulating market growth. The shift towards preventative healthcare and personalized medicine also plays a crucial role, as individuals increasingly prioritize proactive health management and tailored treatment strategies that rely heavily on diagnostic data. However, market growth is not without its challenges. Regulatory hurdles and stringent quality control requirements for laboratory services can pose significant barriers to entry and expansion for smaller players. The high cost associated with advanced diagnostic technologies and skilled labor remains a factor influencing operational expenses and potentially impacting accessibility in certain regions. Additionally, the increasing demand for data security and privacy, particularly given the sensitive nature of patient information, requires robust infrastructure and compliance with stringent regulations. Despite these constraints, the long-term outlook for the clinical laboratory diagnostics services market remains highly positive, driven by ongoing technological innovations and the increasing focus on preventive and personalized healthcare globally. Significant regional variations exist, with North America and Europe currently holding the largest market share due to advanced healthcare infrastructure and high healthcare expenditure. However, emerging economies in Asia-Pacific and other regions are showing promising growth potential as healthcare infrastructure improves and diagnostic awareness increases.

In 2023, Swiss company Roche had the highest revenue worldwide from medical diagnostics, at almost 16.8 billion U.S. dollars. This was closely followed by GE Healthcare, which had a revenue from diagnostics of around 16.3 billion U.S. dollars. In vitro diagnostics (IVD) are one of the prominent segments of the diagnostics industry overall. Although also included in the industry are devices which scan or image parts of the body such as MRIs, CT scans, and ultrasounds. Market share in the IVD markets In 2022, Roche occupied 23 percent of the IVD market in the United States, followed by Abbott laboratories with 20 percent market share. Similarly, Roche diagnostics and Abbott laboratories had the largest market share in Europe in the given year. IVD industry revenue and market size The outbreak of the COVID-19 pandemic caused a huge demand for tests that could detect the disease. The IVD industry therefore underwent massive growth in 2020 and 2021. In 2024, the global revenue of the in vitro diagnostics industry amounted to nearly 99 billion U.S. dollars, with an expected growth to 110 billion U.S. dollars by 2028.